Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Andrea Guennoun, Heba Sidahmed, Cristina Maccalli, Barbara Seliger, Francesco M. Marincola & Davide Bedognetti. (2016) Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology 12:8, pages 879-893.
Read now
Read now
Articles from other publishers (17)
Saurav S. Rout, Yunyun Di, Ulf Dittmer, Kathrin Sutter & Kerry J. Lavender. (2022) Distinct effects of treatment with two different interferon-alpha subtypes on HIV-1-associated T-cell activation and dysfunction in humanized mice. AIDS 36:3, pages 325-336.
Crossref
Crossref
Patrick G. Holder, Shion A. Lim, Christine S. Huang, Preeti Sharma, Yavuz S. Dagdas, Beyza Bulutoglu & Jonathan T. Sockolosky. (2022) Engineering interferons and interleukins for cancer immunotherapy. Advanced Drug Delivery Reviews 182, pages 114112.
Crossref
Crossref
Derry K Mercer, Marie-Louise FrancisDouglas Fraser-Pitt. (2021) Antimicrobial immunotherapeutics: past, present and future. Emerging Topics in Life Sciences 5:5, pages 609-628.
Crossref
Crossref
Henner Stege, Maximilian Haist, Ulrike Nikfarjam, Michael Schultheis, Jaqueline Heinz, Saskia Pemler, Carmen Loquai & Stephan Grabbe. (2021) The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. Targeted Oncology 16:5, pages 537-552.
Crossref
Crossref
Kathrin Sutter, Kerry J. Lavender, Ronald J. Messer, Marek Widera, Katie Williams, Brent Race, Kim J. Hasenkrug & Ulf Dittmer. (2019) Concurrent administration of IFNα14 and cART in TKO-BLT mice enhances suppression of HIV-1 viremia but does not eliminate the latent reservoir. Scientific Reports 9:1.
Crossref
Crossref
Debora Basile, Camilla Lisanti, Maria A. Pizzichetta, Paolo Baldo, Giulia Fornasier, Francesco Lo Re, Giuseppe Corona & Fabio Puglisi. (2019) Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. Recent Patents on Anti-Cancer Drug Discovery 14:3, pages 203-225.
Crossref
Crossref
Kim J. Hasenkrug, Kerry J. Lavender, Mario L. Santiago, Kathrin Sutter & Ulf Dittmer. (2019) Different Biological Activities of Specific Interferon Alpha Subtypes. mSphere 4:4.
Crossref
Crossref
Svetomir N. Markovic & Anagha Bangalore Kumar. 2018. The Basics of Cancer Immunotherapy. The Basics of Cancer Immunotherapy
21
37
.
Ruan F.V. Medrano, Aline Hunger, Samir Andrade Mendonça, José Alexandre M. Barbuto & Bryan E. Strauss. (2017) Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget 8:41, pages 71249-71284.
Crossref
Crossref
Melinda Liu, Yuan Yu M. Huang, Sylvia Hsu & Joseph S. Kass. (2016) Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications. CNS Drugs 30:12, pages 1149-1168.
Crossref
Crossref
Naoya Yamazaki, Hisashi Uhara, Hidefumi Wada, Kenji Matsuda, Keiko Yamamoto, Takashi Shimamoto & Yoshio Kiyohara. (2016) Phase I study of pegylated interferon‐alpha‐2b as an adjuvant therapy in Japanese patients with malignant melanoma. The Journal of Dermatology 43:10, pages 1146-1153.
Crossref
Crossref
Kerry J. Lavender, Kathrin Gibbert, Karin E. Peterson, Erik Van Dis, Sandra Francois, Tyson Woods, Ronald J. Messer, Ali Gawanbacht, Janis A. Müller, Jan Münch, Katie Phillips, Brent Race, Michael S. Harper, Kejun Guo, Eric J. Lee, Mirko Trilling, Hartmut Hengel, Jacob Piehler, Jens Verheyen, Cara C. Wilson, Mario L. Santiago, Kim J. Hasenkrug & Ulf Dittmer. (2016)
Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection
In Vivo
. Journal of Virology 90:13, pages 6001-6013.
Crossref
Crossref
Belinda S. Parker, Jai Rautela & Paul J. Hertzog. (2016) Antitumour actions of interferons: implications for cancer therapy. Nature Reviews Cancer 16:3, pages 131-144.
Crossref
Crossref
Stefan S. BielackSigbjørn SmelandJeremy S. WhelanNeyssa MarinaGordana JovicJane M. HookMark D. KrailoMark GebhardtZsuzsanna PápaiJames MeyerHelen NadelR. Lor RandallClaudia DeffenbaughRajaram NagarajanBernadette BrennanG. Douglas LetsonLisa A. TeotAllen GoorinDaniel BaumhoerLeo KagerMathias WernerChing C. LauKirsten Sundby HallHans GelderblomPaul MeyersRichard GorlickReinhard WindhagerKnut HelmkeMikael ErikssonPeter M. HoogerbruggePaula SchombergPer-Ulf TunnThomas KühneHeribert JürgensHenk van den BergTom BöhlingSusan PictonMarleen RenardPeter ReichardtJoachim GerssTrude Butterfass-BahloulCarol MorrisPancras C.W. HogendoornBeatrice SeddonGabriele CalaminusMaria MichelagnoliCatharina DhoogeMatthew R. SydesMark Bernstein. (2015) Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. Journal of Clinical Oncology 33:20, pages 2279-2287.
Crossref
Crossref
Brian Gowen, Jane Ennis, Kevin Bailey, Zachary Vest, Dionna Scharton, Eric Sefing & Jeffrey Turner. (2014) Single-Dose Intranasal Treatment with DEF201 (Adenovirus Vectored Consensus Interferon) Prevents Lethal Disease Due to Rift Valley Fever Virus Challenge. Viruses 6:3, pages 1410-1423.
Crossref
Crossref
Holger H H Erb, Regina V Langlechner, Patrizia L Moser, Florian Handle, Tineke Casneuf, Karin Verstraeten, Bettina Schlick, Georg Schäfer, Brett Hall, Kate Sasser, Zoran Culig & Frédéric R Santer. (2013) IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9. Endocrine-Related Cancer 20:5, pages 677-689.
Crossref
Crossref
Francesca Pretto & Dario Neri. (2013) Pharmacotherapy of metastatic melanoma: Emerging trends and opportunities for a cure. Pharmacology & Therapeutics 139:3, pages 405-411.
Crossref
Crossref